Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amicas agrees to Merge Healthcare takeover

This article was originally published in The Gray Sheet

Executive Summary

Imaging IT solutions provider Amicas agrees to be acquired by health IT firm Merge Healthcare after determining that the $248 million purchase price was a better offer than Amicas' previous $217 million deal to be bought out by private equity investment firm Thoma Bravo, Amicas announces March 5. Following the initial $5.35-per-share Thoma Bravo deal last December, Amicas announced Feb. 24 that it was considering a revised $6.05-per-share bid from Merge Healthcare (1"The Gray Sheet" March 1, 2010). Amicas will now pay an $8.6 million termination fee to Thoma Bravo (half of which will be reimbursed by Merge) and enter into a definitive merger agreement with Merge (2"The Gray Sheet" Jan. 4, 2010). The combination will "create a leading global healthcare IT provider and a pure-play medical imaging software vendor," Amicas says. Combined offerings will "range from comprehensive automation solutions for cardiology and radiology providers to enterprise content management solutions for [integrated delivery networks] to [original equipment manufacturer] solutions for health IT applications to trial, site and patient management solutions for pharmaceutical, biotechnology, medical device and contract research organizations.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel